Author: Ravi Shankar

Strategic partnership delivers operational continuity today and a multi-year plan to strengthen Columbia Sportswear’s European supply chain

PARIS, France, Sept. 29, 2026 (GLOBE NEWSWIRE) — GXO Logistics, Inc. (NYSE: GXO), the world’s largest pure-play contract logistics provider, today announced the launch of a new 10-year strategic relationship with Columbia Sportswear Company, a global leader in outdoor, active and lifestyle products. GXO is now managing Columbia’s European distribution center in Cambrai, France.

“We are proud to serve Columbia Sportswear in Europe,” said Vincent Ricci, Managing Director, GXO France. “Our team has delivered a seamless transition of this critical distribution operation, and together we have established a multi-year roadmap that is designed to enhance agility and strengthen Columbia Sportswear’s supply chain across the region.”

Matthieu Schegg, SVP & GM for EMEA, Columbia Sportswear, said: “At Columbia Sportswear, we partner with world‑class experts like GXO, as we advance our distribution and logistics transformation, leveraging their capabilities to strengthen our supply chain in Europe and deliver consistent multi‑channel service for our customers.”

Supporting Columbia’s European operations
The distribution center operated by GXO is located in Cambrai, Northern France, and is Columbia Sportswear’s primary distribution hub for continental Europe, supporting e-commerce fulfillment, retail replenishment and wholesale distribution. From this strategic location, GXO will manage inbound logistics, storage, order fulfillment and outbound distribution activities serving multiple European markets.

The transition was prepared jointly by Columbia Sportswear and GXO with a focus on operational continuity, employee integration and maintaining uninterrupted service for customers.

GXO in France
GXO has been helping customers in France optimize their logistics for several decades and operates over 60 warehouses throughout the country. Currently ranked the #2 logistics service provider in France by Supply Chain Magazine, GXO manages logistics for customers in a variety of sectors, including ecommerce, retail, FMCG and technology. In France, GXO employs nearly 8,500 team members.

About Columbia Sportswear Company
Columbia Sportswear Company connects active people with their passions and is a global multi-brand leading innovator in outdoor, active and lifestyle products including apparel, footwear, accessories, and equipment. Founded in 1938 in Portland, Oregon, the Company’s brands are sold in 122 countries. In addition to the Columbia® brand, Columbia Sportswear Company also owns the Mountain Hard Wear®, SOREL® and prAna® brands. To learn more, please visit the Company’s websites at www.columbia.com, www.mountainhardwear.com, www.sorel.com, and www.prana.com.

About GXO Logistics
GXO Logistics, Inc. (NYSE: GXO) is the world’s largest pure-play contract logistics provider and is positioned to capitalize on the rapid growth of ecommerce, automation and outsourcing. GXO has more than 150,000 team members across more than 1,000 facilities totaling more than 200 million square feet. The company serves the world’s leading blue-chip companies to solve complex logistics challenges with technologically advanced supply chain and ecommerce solutions, at scale and with speed. GXO corporate headquarters is in Greenwich, Connecticut. Visit GXO.com for more information and connect with GXO on LinkedIn, X, Facebook, Instagram and YouTube.

Media contacts
Claudia Roux 
+33 (0)6 28 45 59 72
claudia.roux@gxo.com 

Matthew Schmidt 
+1 203-307-2809 
matt.schmidt@gxo.com

CARMEL, Ind., Sept. 29, 2026 (GLOBE NEWSWIRE) — NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced the appointment of Craig Blanchard as Chief Commercial Officer. In this role, Mr. Blanchard will oversee the Company’s commercial functions, including sales and marketing.

The appointment of Mr. Blanchard as Chief Commercial Officer represents a strategic investment in the significant growth opportunity NeurAxis sees ahead. With the Company expecting to expand its commercial organization alongside a substantial increase in covered lives, NeurAxis is strengthening its leadership and sales infrastructure to support broader adoption of IB-Stim and capitalize on its expanding market opportunity.

“Craig joins NeurAxis at an important inflection point in our commercial growth,” said Brian Carrico, President and Chief Executive Officer of NeurAxis. “As we prepare to significantly expand our commercial organization and anticipate a substantial increase in covered lives, his experience building sales teams, launching innovative medical technologies and driving market adoption will be invaluable. We believe Craig’s leadership will help us translate expanding reimbursement coverage into broader physician adoption and increased patient access to IB-Stim.”

Mr. Blanchard brings NeurAxis extensive experience in commercialization, market development, and healthcare technology adoption. Previously, he served as Vice President of Product Strategy, Marketing and Field Clinical at NICO Corporation, where he led commercial strategy for minimally invasive neurosurgery technologies and helped drive multiple products from launch through market adoption, with NICO technologies impacting more than 40,000 patients and leading to its acquisition by Stryker in 2024.

Earlier in his career, Mr. Blanchard held commercial leadership roles at Boston Scientific and Guidant Corporation, with responsibilities spanning sales growth, national accounts, and product commercialization.

NeurAxis’ proprietary PENFS technology, IB-Stim, is FDA-cleared for the treatment of functional abdominal pain associated with irritable bowel syndrome (IBS) and Functional Dyspepsia, and FD associated nausea symptoms, in patients 8 years and older. IB-Stim is a non-invasive neuromodulation device that gently stimulates cranial nerve bundles in the ear to help regulate pain signaling between the gut and the brain. Currently, no FDA-approved drug therapies exist for pediatric patients with abdominal pain-related disorders of gut-brain interaction (DGBIs), a significant unmet medical need. In the absence of approved options, off-label prescription drugs are often used, despite limited efficacy data and potential safety concerns—underscoring IB-Stim’s unique position as the only FDA-cleared therapy specifically designed for this large and underserved pain related patient population.

About NeurAxis, Inc.
NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive the adoption of IB-Stim, its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is FDA-cleared for functional abdominal pain in irritable bowel syndrome (IBS) and functional dyspepsia, including FD-linked nausea symptoms in patients ages 8 and older. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway. For more information, please visit http://neuraxis.com.

Contacts:

Company
NeurAxis, Inc.
info@neuraxis.com
For contraindications, precautions, warnings, and IFU, please see: https://ibstim.com/important-information/.

Investor Relations
Lytham Partners
Ben Shamsian
646-829-9701
shamsian@lythampartners.com

Appointment adds rare-earth project execution experience and strengthens collaboration with SRC as REalloys advances commercialization and its U.S. mine-to-magnet strategy.

EUCLID, Ohio, Sept. 29, 2026 (GLOBE NEWSWIRE) — REalloys Inc. (NASDAQ: ALOY) (“REalloys” or the “Company”), an integrated U.S. rare-earth materials and permanent magnet company, today provided additional details regarding the previously announced appointment of Dr. Muhammad Imran, Ph.D., P.Eng., C.Dir., as Chief Operating Officer. As previously disclosed, Dr. Imran’s appointment became effective September 1, 2026.

Dr. Imran has more than 17 years of experience at the SRC, most recently as Chief Technology Officer and Vice President. Since 2020, he led SRC’s Rare Earth Element Division, playing a key leadership role within the multidisciplinary team responsible for developing SRC’s Rare Earth Processing Facility in Saskatoon, Saskatchewan.

His appointment builds on an established commercial relationship that combines SRC’s proprietary processing technologies, technical expertise and project delivery capabilities with REalloys’ downstream manufacturing and market development activities. The relationship supports commercialization of SRC’s technologies and production while advancing REalloys’ access to North American rare-earth materials.

“Muhammad brings valuable experience in rare-earth technology development, scale-up and capital-project execution,” said Lipi Sternheim, Chief Executive Officer of REalloys. “His understanding of SRC’s processing platform and experience working with its technical teams will help us coordinate effectively as we advance our contracted projects. SRC’s continuing technology leadership and delivery capabilities are central to our near-term commercialization plans, and Muhammad’s appointment strengthens our ability to translate that partnership into commercial progress.”

SRC’s Rare Earth Processing Facility is being developed as one of North America’s first integrated rare-earth processing platforms, spanning hydrometallurgical processing, separation and metallization. SRC’s experienced team continues to advance the facility through commissioning and toward integrated commercial production in 2027.

At SRC, Dr. Imran helped build and lead multidisciplinary teams advancing SRC’s proprietary rare-earth processing technologies through development, scale-up and commercialization. These teams designed and fabricated more than 400 custom solvent-extraction cells, supporting separation capabilities for NdPr and heavy rare-earth products, including dysprosium and terbium, and advanced automated metallization technology for producing high-purity rare-earth metals.

Dr. Imran also helped shape a technology strategy incorporating automation, advanced process control and AI-enabled process optimization. SRC’s scientists, engineers and technical specialists continue to develop these capabilities and deliver the facility and associated projects.

Supporting Near-Term Commercialization

Dr. Imran’s appointment comes as REalloys advances projects with SRC intended to support its near-term rare-earth supply and longer-term manufacturing strategy.

Through the Company’s strategic relationship with SRC, approximately 150 metric tons per year of NdPr metallization capacity is targeted for commissioning in the first quarter of 2027, followed by planned fully integrated production from monazite concentrate through separated rare-earth products to metals in the third quarter of 2027. These targets remain subject to successful project execution, commissioning and production ramp-up.

Dr. Imran will lead REalloys’ participation in its projects with SRC, working closely with SRC’s leadership and technical teams on project requirements, execution interfaces and commercial readiness, including the planned light and heavy rare-earth metallization facilities. SRC will continue to lead delivery of its contracted technology development, engineering and commissioning responsibilities.

Under existing offtake agreements, REalloys has contracted to purchase the majority of SRC’s planned production of specified rare-earth products, including NdPr metal and dysprosium and terbium oxides, within the quantities and term covered by those agreements. The arrangement provides SRC with an anchor customer for its production and gives REalloys a potential source of supply to support downstream manufacturing and customer sales.

As production ramps up, deliveries under these agreements are expected to support REalloys’ revenue generation from SRC-supplied materials while the Company develops its broader mine-to-magnet platform. The organizations’ complementary roles connect Canadian processing innovation and production with U.S. downstream manufacturing and market opportunities.

Advancing REalloys’ Operational Strategy

As Chief Operating Officer, Dr. Imran will lead REalloys’ engineering and processing activities, capital-project execution, technology scale-up, supply-chain development and advancement of its integrated mine-to-magnet platform.

REalloys is developing processing infrastructure intended to utilize diverse domestic, allied and recycled feedstocks, advancing capabilities across rare-earth separation, oxide production, metallization and permanent magnet manufacturing.

“North America has significant rare-earth resources. The critical challenge is building the industrial infrastructure and technical capabilities needed to transform those resources into separated products, metals and ultimately magnets,” said Dr. Imran. “At SRC, I had the privilege of helping lead a multidisciplinary team developing those capabilities. I look forward to continuing to work closely with that team in my new role, connecting SRC’s processing and technology expertise with REalloys’ downstream manufacturing and commercial objectives. Effective collaboration between our organizations will be important as we advance these projects and build toward larger-scale production.”

Dr. Imran holds a Ph.D. and MASc in Chemical Engineering and the Professional Engineer (P.Eng.) and Chartered Director (C.Dir.) designations. His experience combines rare-earth and chemical-processing expertise with technology commercialization and execution of complex industrial projects.

About REalloys
REalloys Inc. (NASDAQ: ALOY) is a U.S.-based rare earth materials company executing a mine-to-magnet strategy across upstream feedstock, midstream separation and metallization, and downstream magnet manufacturing. REalloys is focused on delivering qualified, allied-nation rare earth metals and alloys including dysprosium, terbium, praseodymium and neodymium to the U.S. Department of Defense, the U.S. Department of Energy, NASA, the U.S. Defense Industrial Base, and the broader U.S. Organic Industrial Base.

For more information, please visit www.REalloys.com or email InvestInAmerica@REalloys.com.

Safe Harbor Statement and Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding REalloys’ commercialization strategy; the anticipated commissioning and production ramp of rare-earth processing and metallization capabilities at the Saskatchewan Research Council (“SRC”); the targeted commissioning of approximately 150 metric tons per year of NdPr metallization capacity in the first quarter of 2027; the planned commencement of integrated production from monazite concentrate through separated rare-earth products and metal in the third quarter of 2027; REalloys’ anticipated access to and commercialization of SRC production; the timing and potential generation of commercial revenues; the development, scale-up and operation of REalloys’ rare-earth processing, metallization and permanent-magnet manufacturing capabilities; and the anticipated contributions of Dr. Muhammad Imran to these activities.

These forward-looking statements are based on current expectations, estimates, projections, and assumptions that involve significant risks and uncertainties. Actual results may differ materially from those expressed or implied by these forward-looking statements due to a variety of factors, including, but not limited to: construction, installation, commissioning and production-ramp risks; delays in achieving targeted production capacity or product specifications; technological and operational challenges; the availability, quality and cost of rare-earth feedstocks; supply-chain disruptions; fluctuations in rare-earth prices and customer demand; the ability to successfully commercialize and sell rare-earth products; the availability of financing and government support; changes in market conditions; changes in applicable laws, regulations or government policies; and other risks described from time to time in REalloys’ filings with the U.S. Securities and Exchange Commission (“SEC”), including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings.

There can be no assurance that SRC’s planned commissioning, production ramp or integrated monazite-to-metal production will occur within the anticipated timeframes or achieve the targeted production capacities, or that such production will result in commercial revenues to REalloys at the levels or within the timeframes currently anticipated.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as required by applicable law, REalloys undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Disclosure Information

REalloys uses and intends to continue using its investor website at www.REalloys.com as a means of disclosing material non-public information and for complying with Regulation FD. Investors should monitor this site, along with the Company’s press releases, SEC filings, public conference calls, and webcasts.

VANCOUVER, British Columbia, Sept. 29, 2026 (GLOBE NEWSWIRE) — Sable Resources Ltd. (“Sable” or the “Company”) (TSXV:SAE | OTCQB:SBLRF) is pleased to announce that its partner, Moxico Resources plc (“Moxico”), has approved funding for the upcoming spring-summer exploration season at the El Fierro Project in San Juan Province, Argentina.

The approved exploration program includes regional geological reconnaissance and target generation across underexplored areas of the El Fierro property, a Spartan Magnetotelluric (“MT”) geophysical survey to be conducted by Quantec Geoscience, and 3,500 metres of diamond drilling at the Pyros porphyry Cu-Au-Mo system.

Regional exploration will focus particularly on the southwestern portion of Sable’s large El Fierro land package, where extensive areas have received limited detailed exploration to date. The objective of this work is to evaluate additional prospective areas and generate new targets outside the currently known Pyros mineralized system.

The planned MT geophysical survey will cover the entire Pyros porphyry system with a vertical penetration of up to 2km and will be integrated with existing geological, geochemical, and geophysical datasets to help refine the new drill phase. MT has become an essential tool for porphyry exploration with conductivity anomalies showing strong correlation with Cu-Au-Mo mineralization in many Andean porphyry systems such as Altar, Valeriano, Piuquenes, and many other examples around the world.

Regional field exploration and the MT geophysical survey is planned to commence in November 2026, with drilling anticipated to commence during the second week of January 2027.

Dr. Ruben Padilla, President and CEO of Sable, stated, “We are pleased that Moxico has approved the next phase of exploration at El Fierro. The program provides a good balance between advancing the Pyros porphyry system through an additional 3,500 metres of drilling and continuing systematic exploration across the land package. To date, most drilling at Pyros has focused on the central portion of the known porphyry footprint. The upcoming drill program is designed to extend the known ring-shaped Cu-Au-Mo mineralization, expand the high-grade breccia zones intersected in previous drilling, and begin testing the undrilled southern and western extensions of the system. We consider the southern area particularly important, as the main sericite-chlorite mineralizing event may be better preserved in this part of the system.”

QUALIFIED PERSON

Luis Arteaga M.Sc. P.Geo., Vice President Exploration, is the Company’s Qualified Person as defined by NI 43-101. He has reviewed and approved the technical information in this news release.

ABOUT THE EL FIERRO PROJECT

El Fierro Project is located 250 km northwest of San Juan city, and 110 km south of the world-class Vicuna district which contains the Josemaria, Filo del Sol, and Lunahuasi deposits. El Fierro is a large (10 km x 10 km) Miocene magmatic–hydrothermal system surrounding the Pyros Cu-Au-Mo porphyry centre; Pyros was discovered by Sable during the 2021-2022 drilling campaign. Sable drilled 13 holes at Pyros in 2022, discovering a large, multiphase Miocene-age stock hosted within Permian granitic rocks. Multiple holes intercepted significant intervals of Cu-Mo-Au mineralization. On February 27, 2025, the Company entered into an agreement with Moxico Resources, which grants Moxico an option to earn up to a 51% interest in the El Fierro Project by completing a series of exploration expenditures and payments over five years, with the option to earn up to 70% by completing a feasibility study.
  
ABOUT SABLE RESOURCES LTD.

Sable is a well-funded junior grassroots explorer focused on the discovery of Tier-One new precious metal and copper projects through systematic exploration in endowed terranes located in favorable, established mining jurisdictions. Sable’s focus is developing its large portfolio of new Greenfields projects to resource level.  Sable is actively exploring the San Juan Regional Program (120,800 ha) incorporating the Don Julio, El Fierro, Zorro, and Cerro Negro projects in San Juan, Argentina and the Copper Queen (15,133 ha), Copper Prince (3,980 ha), and Core Mountain (1,925 ha) properties in British Columbia.

For further information, please contact:

Ruben Padilla, President & CEO at ruben.padilla@sableresources.com or +1 (520) 488-2520
Related link: sableresources.com

Neither the TSX Venture Exchange nor its Regulation Services Provider, as that term is defined in the policies of the TSX Venture Exchange, accepts responsibility for the adequacy or accuracy of this release.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Sable’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. Although such statements are based on reasonable assumptions of Sable’s management, there can be no assurance that any conclusions or forecasts will prove to be accurate.

While Sable considers these assumptions to be reasonable based on information currently available, they may prove to be incorrect. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors include risks inherent in the exploration and development of mineral deposits, including risks relating to changes in project parameters as plans continue to be redefined, risks relating to variations in grade or recovery rates, risks relating to changes in mineral prices and the worldwide demand for and supply of minerals, risks related to increased competition and current global financial conditions, access and supply risks, reliance on key personnel, operational risks, and regulatory risks, including risks relating to the acquisition of the necessary licenses and permits, financing, capitalization and liquidity risks.

The forward-looking information contained in this release is made as of the date hereof, and Sable is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

TORONTO, Sept. 29, 2026 (GLOBE NEWSWIRE) — First Quantum Minerals Ltd. (“First Quantum” or the “Company”) (TSX: FM) will release third quarter 2026 financial and operating results on Wednesday, October 28, 2026 after the close of the Toronto Stock Exchange (“TSX”). The Company will host a conference call and webcast to discuss the results on Thursday, October 29, 2026 at 9:00 am (ET).

Conference call and webcast details:
Toll-free North America: 1-800-715-9871
International: +1-646-307-1963
Conference ID: 8111752
Webcast: Direct link or on our website

A replay of the webcast will be available on the First Quantum website.

About First Quantum

First Quantum is engaged in the production of copper, nickel and gold, and related activities including exploration and development. The Company has operating mines located in Zambia and Mauritania. The Company’s Cobre Panamá mine was placed into a phase of Preservation and Safe Management in November 2023. The Company’s Ravensthorpe mine was placed into a care and maintenance process in May 2024. The Company is progressing the Taca Taca copper-gold-molybdenum project in Argentina and is exploring the La Granja and Haquira copper deposits in Peru.

For further information, visit our website at www.first-quantum.com or contact:

Investor Relations:
Bonita To, Director, Investor Relations & Capital Markets
(416) 361-6400
Toll-free: 1 (888) 688-6577
E-Mail: info@fqml.com

Media Relations:
James Devas, Manager, Corporate Affairs
+44 207 291 6630
E-Mail: james.devas@fqml.com

TORONTO, Sept. 29, 2026 (GLOBE NEWSWIRE) — Halcones Precious Metals Corp. (TSXV: HPM) (the “Company” or “Halcones”), further to its press release dated October 20, 2025, announces that Minera Los Halcones SpA (“Minera Halcones”), Halcones’ wholly-owned subsidiary, has been advised that the independent Court-appointed expert has submitted her compensation valuation report to the Civil Court of Taltal, Chile (the “Court”) in connection with the application before the Court to obtain surface rights access to the Polaris project (“Polaris” or the “Project”).

Halcones, representing Austral Exploraciones SpA (“Austral”), the owner of the Polaris mining concessions that have been optioned by the Company pursuant to a binding option agreement with Austral, continues to pursue obtaining an easement for surface access to diamond drill the Project through the Chilean legal system before the Court. The legal proceedings were initiated on October 30, 2025, and over the last few months all the Court’s requests for additional information have been satisfied. The Court has been asked to rule on the surface access easement. Under Chilean law, similar to many jurisdictions including Canada, mineral rights, which are owned by the state, have preference over surface rights and there is a well-established process that will be followed to achieve access and arrange compensation for the surface rights holder. The Company continues to seek a negotiated agreement with the surface rights holders while the legal process proceeds but intends to pursue all legal avenues to obtain Polaris surface access as soon as possible.

With the submission of the expert report, the evidentiary stage of the proceeding is now substantially complete, and the matter is moving toward resolution by the Court. The expert’s mandate was to quantify the compensation payable, and the report sets out the amounts of compensation payable to the surface rights owners.

Although there is no set timeline for a decision by the Court, the fact that there is now no other pending procedures necessary is a positive sign and the Company looks forward to a decision from the Court shortly.

About Halcones Precious Metals Corp.

Halcones is focused on exploring for and developing gold-silver projects in Chile. The Company has a team with a strong background of exploration success in the region.

For further information, please contact:

Vincent Chen, CPA
Investor Relations
Vincent.chen@halconespreciousmetals.com
www.halconespreciousmetals.com
647-276-0540

Cautionary Note Regarding Forward-looking Information

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, without limitation, amendments to the Polaris Option Agreement, surface rights access to the Polaris project, a ruling by the Court, the timing and outcome of the easement proceeding and the Company’s future plans. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward- looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Halcones, as the case may be, to be materially different from those expressed or implied by such forward-looking information, including but not limited to: general business, economic, competitive, geopolitical and social uncertainties; the actual results of current exploration activities; risks associated with operation in foreign jurisdictions; ability to successfully integrate the purchased properties; foreign operations risks; and other risks inherent in the mining industry. Although Halcones has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. Halcones does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Milestone reflects continued progress in collaboration to develop a novel class of degrader antibody conjugates, or DACs

BRISBANE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced the achievement of a $7 million research milestone under its strategic collaboration with Pfizer for the discovery and development of degrader antibody conjugates (DACs).

Nurix entered into the collaboration with Seagen Inc., now part of Pfizer, in September 2023. Under the terms of the agreement, Nurix received an upfront payment of $60 million and became eligible to receive up to $3.4 billion in potential research, development, regulatory and commercial milestone payments across multiple programs, as well as mid-single-digit to low-double-digit percentage tiered royalties on future product sales. Nurix also retains an option for U.S. profit sharing and co-promotion on up to two products arising from the collaboration. In connection with today’s announcement, Nurix will receive a $7 million milestone payment from Pfizer, which will bring the total amount received under this agreement to $82 million.

About Degrader Antibody Conjugates (DACs)
DACs are an emerging therapeutic modality designed to combine the cell and tissue selectivity of antibodies with the catalytic mechanism of targeted protein degraders. Unlike traditional antibody-drug conjugates (ADCs), which typically deliver cytotoxic payloads to antigen-expressing cells, DACs deliver targeted protein degraders designed to eliminate specific disease-driving proteins. This approach has the potential to provide multiple layers of selectivity based on cell-surface antigen expression, the intracellular protein target and E3 ligase expression.

About Nurix Therapeutics, Inc.
Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, a new frontier in drug discovery aimed at improving treatment options for patients with cancer and autoimmune diseases. Nurix’s clinical-stage oncology pipeline includes bexobrutideg, a degrader of BTK being co-developed with Roche, and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix’s autoimmune disease pipeline includes bexobrutideg in collaboration with Roche and clinical-stage degraders of IRAK4 in collaboration with Gilead and STAT6 in collaboration with Sanofi. Nurix is also advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates in its wholly owned preclinical pipeline and under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by an AI-integrated discovery engine capable of tackling virtually any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease. Nurix is headquartered in Brisbane, California. For additional information, visit www.nurixtx.com.

Forward-Looking Statements
This press release contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements that reflect Nurix’s expectations, assumptions or projections about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements regarding: Nurix’s expectations for its collaboration with Pfizer; the potential benefits of Nurix’s collaboration with Pfizer; the potential benefits of degrader antibody conjugates; and the potential achievement of milestone, royalty and license payments under the Nurix-Pfizer collaboration. Forward-looking statements reflect Nurix’s current beliefs, expectations, and assumptions. Although Nurix believes such expectations and assumptions are reasonable, Nurix can give no assurance that they will prove to be correct. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and changes in circumstances that are difficult to predict, which could cause Nurix’s actual activities and results to differ materially from those expressed in any forward-looking statement. Such risks and uncertainties include, but are not limited to: (i) the ability of each party to perform its obligations under the Nurix-Pfizer collaboration; (ii) whether the parties will be able to successfully conduct and complete preclinical development, clinical development and commercialization of any drug candidates under the Nurix-Pfizer collaboration; (iii) the unexpected emergence of adverse events or other undesirable side effects during preclinical and clinical development; (iv) whether Nurix will be able to fund development activities and achieve development goals, including those under the Nurix-Pfizer collaboration; (v) risks and uncertainties relating to the timing and receipt of payments from Nurix’s collaboration partners, including milestone payments and royalties on future potential product sales; and (vi) other risks and uncertainties described under the heading “Risk Factors” in Nurix’s Quarterly Report on Form 10-Q for the fiscal period ended May 31, 2026, and other SEC filings. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. The statements in this press release speak only as of the date of this press release, even if subsequently made available by Nurix on its website or otherwise. Nurix disclaims any intention or obligation to update publicly any forward-looking statements, whether in response to new information, future events, or otherwise, except as required by applicable law.

Contacts:
Media and Investors
Kris Fortner
Nurix Therapeutics, Inc.
ir@nurixtx.com

Exercise of existing purchase option has been completed in conjunction with growing commercialization opportunities

MONTREAL, Sept. 29, 2026 (GLOBE NEWSWIRE) — PyroGenesis Inc. (“PyroGenesis” or the “Company”) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), a leader in ultra-high temperature processes and engineering innovation, and a plasma-based technology provider to heavy industry & defense, announces that is has completed the acquisition of a 50% ownership interest in HPQ Silica Polvere Inc. (“HSPI”). HSPI’s primary line of business is commercialization of the Fumed Silica Reactor (the “FSR”), a proprietary technology originally developed and built by PyroGenesis to convert quartz (SiO₂) into fumed silica in a single and eco-friendly step while eliminating the use of harmful chemicals generated by conventional methods.

Fumed silica is a widely used industrial material found in thousands of products. If commercially successful, the FSR could significantly advance the reshoring of fumed silica production from China-based producers to domestic facilities by enabling localized, modular, and on-demand fumed silica production near end users’ manufacturing facilities across North America.

Before completion of the acquisition, HSPI was a wholly-owned subsidiary of HPQ Silicon Inc. (“HPQ”). Since 2021 [press release dated July 6, 2021], PyroGenesis has held: (i) a 10% annual royalty on HSPI’s sales (the “Royalty”) of fumed silica, (ii) the rights, under an agreement with HPQ, to convert the Royalty into a 50% interest in HSPI, and (iii) an exclusive arrangement to be the sole supplier of equipment relating to any commercialization of the FSR.

PyroGenesis previously announced its intention to convert the Royalty into an ownership interest [press release dated May 30, 2024]. With the completion of the acquisition announced today, the Royalty has been converted into a 50% ownership interest in HSPI. PyroGenesis also retains its exclusive arrangement to serve as the sole supplier of equipment relating to any commercialization of the FSR.

“The market opportunities for the fumed silica reactor technology continue to grow, and we now have partnership interest across multiple sectors and geographies,” said Mr. P. Peter Pascali, President and CEO of PyroGenesis. “Completing the 50% ownership agreement in HSPI was a necessary step to properly engage with additional clients around the world who have recently expressed interest in the FSR technology and production capabilities.”

Image 1: containers of fumed silica produced by PyroGenesis’ fumed silica reactor.

UPDATE ON COMMERCIAL DEVELOPMENTS

In August, the Company provided an update on its fumed silica business line [press release August 17, 2026], including its commercial potential and the status of recent customer interest, specifically regarding four separate entities. Since that release, the following developments have occurred:

1. The first entity is a Global Manufacturer of fumed silica, who previously had signed a letter of intent [announced July 9, 2024] that outlined the basis of collaboration between the entity and PyroGenesis and Polvere during the pilot scale phase of the FSR development. As per the signed MOU, the goal of the pilot scale phase was to validate the ability of the FSR to produce low-cost, low carbon material acceptable to the manufacturer’s specifications.

   The Company reported previously that following the successful completion of the fumed silica reactor pilot program objectives, the parties are evaluating potential frameworks for the next phase of their collaboration, including opportunities to support the commercial deployment of the FSR.

   The Company reports today that discussions have resumed. An additional meeting is scheduled for the week of September 28 to discuss further details regarding the go-forward framework.

2. The second entity is a potential Joint Venture Partner, with whom the Company reported previously the potential formation of a joint venture (the “JV”) for the purpose of operating a 1,000 tonne per year fumed silica production plant (with the fumed silica produced to be used by the Joint Venture Partner in a new application) and with an expectation that there would be a need for a series of additional fumed silica plants of the same or larger size. It was indicated that the JV is contingent upon the successful negotiation and execution of one or more definitive agreements pertaining to the JV and related obligations by the parties thereto.

   The Company reported previously that discussions were stalled, and that PyroGenesis had proposed a compromise position for which a response had yet to be received at the time of the August release.

   The Company reports today that discussions recently resumed with in-person meetings. A team from PyroGenesis recently returned from one of the client’s U.S. facilities, where meetings were held to discuss proposed changes. The proposed changes were favorably received by both sides and negotiations have actively resumed.

3. The third entity is a potential Asian customer that uses fumed silica in their end product, and who wishes to collaborate in establishing a production facility in North America to better address the local market, with discussions involving large-scale bulk supply of fumed silica and/or local fumed silica production plants. Additionally, the Client had indicated that demand could require several 10,000 tonnes per year FSR systems.

   The Company reports today that discussions with this entity continue, with the entity recently requesting a meeting at PyroGenesis’ headquarters to accelerate the process.

4. (iv) The fourth entity, an existing PyroGenesis customer with significant business operations in the Middle East, indicated a desire for the potential construction of a local fumed silica production plant to serve the Middle Eastern market. Additionally, it was indicated that negotiations planned for the 2nd half of 2026 will help determine the scale of the agreement, potentially focusing on a 10,000 tonnes per year production plant.

   The Company reports today that negotiations are still planned for the 2^nd half of 2026.

INDUSTRY AND MARKET CONTEXT

• Fumed silica is one of the most widely used industrial materials and can be found in thousands of consumers and industrial products, including cosmetics, toothpaste, pet litter, powdered food, milkshakes, instant coffee, pharmaceuticals, agriculture, adhesives, paints, inks, photocopy toner, sealants, fiber optic cables, thermal insulation, construction materials, and batteries, to name a few. It is often used in these products as a thickening/anti-caking agent, used to stabilize and improve the texture, consistency, and flow of the end-product.
• The global fumed silica market is projected to surpass US$2.57 billion by 2034, driven by growing demand in the coatings, sealants, automotive, and lithium-ion battery sectors. ¹
• PyroGenesis was originally engaged to develop and build the FSR pilot plant for HPQ Polvere Inc., a subsidiary of HPQ Silicon Inc.
• PyroGenesis now has a 50% ownership of HSPI (the FSR rights-holder) and exclusive arrangement to be the sole supplier of equipment relating to any FSR commercialization.

About the Fumed Silica Reactor

PyroGenesis is the exclusive supplier of plasma-based technology that uses quartz (SiO₂) as a raw material to produce commercial-grade fumed silica in a single and eco-friendly process while eliminating the use of harmful chemicals generated by certain conventional methods. The FSR requires no additional processes to develop to prepare feedstock, and no intermediary toxic chemical-based processing. The FSR can produce fumed silica from quartz at one physical location. When compared to some multi-step, traditional processing methods, the expected benefits of the FSR process can generally be summarized as follows:

1. Lower capital costs.
2. Lower operating costs.
3. Reduction of CO₂ emissions.
4. Reduction in energy footprint.
5. Elimination of purchase and storage requirements for hazardous chemicals.
6. Simplified logistics/shortened production chain due to the single location, single system, single phase process, and the elimination of feedstock ingredient handling, storage, preparation/transformation, and transportation.
7. Safer production environment due to absence of dangerous, toxic, or explosive chemicals.

About PyroGenesis Inc.

PyroGenesis leverages 35 years of plasma technology leadership to deliver advanced engineering solutions to energy, propulsion, destruction, process heating, emissions, and materials development challenges across heavy industry and defense. Its customers include global leaders in aluminum, aerospace, steel, iron ore, utilities, environmental services, military, and government. From its Montreal headquarters and local manufacturing facilities, PyroGenesis’ engineers, scientists, and technicians drive innovation and commercialization of energy transition and ultra-high temperature technology. PyroGenesis’ operations are ISO 9001:2015 and AS9100D certified, with ISO certification maintained since 1997. PyroGenesis’ shares trade on the TSX (PYR), OTCQX (PYRGF), and Frankfurt (8PY1) stock exchanges.

Cautionary and Forward-Looking Statements

This press release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of applicable securities laws. In some cases, but not necessarily in all cases, forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, “is positioned”, “estimates”, “intends”, “assumes”, “anticipates” or “does not anticipate” or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking statements. Forward-looking statements are not historical facts, nor guarantees or assurances of future performance but instead represent management’s current beliefs, expectations, estimates and projections regarding future events and operating performance. Forward-looking statements are necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by PyroGenesis as of the date of this release, are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ, possibly materially, from those indicated by the forward-looking statements include, but are not limited to, the risk factors identified under “Risk Factors” in PyroGenesis’ latest annual information form, and in other periodic filings that it has made and may make in the future with the securities commissions or similar regulatory authorities, all of which are available under PyroGenesis’ profile on SEDAR+ at www.sedarplus.ca. These factors are not intended to represent a complete list of the factors that could affect PyroGenesis. However, such risk factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. You should not place undue reliance on forward-looking statements, which speak only as of the date of this release. PyroGenesis undertakes no obligation to publicly update or revise any forward-looking statement, except as required by applicable securities laws. Neither the Toronto Stock Exchange, its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) nor the OTCQX Best Market accepts responsibility for the adequacy or accuracy of this press release.

For further information contact ir@pyrogenesis.com or visit http://www.pyrogenesis.com

_____________________________
¹ https://finance.yahoo.com/news/fumed-silica-market-reach-usd-143000439.html

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/210ecdfb-249f-4456-9e77-777a0aac39f8

Appoints Rich Daly, a life sciences executive with more than 30 years of leadership experience across large pharmaceutical companies, emerging biotechnology companies, and public company boards, to its Board of Directors

WARREN, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today announced the appointment of Rich Daly to the Company’s Board of Directors, effective October 14, 2026. Mr. Daly has three decades of leadership experience in large and small biopharmaceutical companies, with a focus on commercial and operating roles.

“I am very pleased to welcome Rich to the Aquestive Board,” said Daniel Barber, President and Chief Executive Officer of Aquestive Therapeutics. “Rich brings extensive experience supporting commercial launches and building biopharmaceutical commercial organizations, including through senior leadership roles at AstraZeneca, Takeda, and Catalyst. His commercial and operating perspective will be valuable and add to the board’s existing commercial experience as we continue our preparations for the potential launch of Anaphylm, if approved by the FDA.”

Following Mr. Daly’s appointment, the Board will consist of eight directors, seven of whom the Board has determined are independent under applicable Nasdaq listing standards.

“We are delighted to welcome Rich to the Board of Directors,” said Gregory B. Brown, M.D., Chairman of the Board of Aquestive. “Rich has built commercial organizations from their earliest stages, led launches of both primary care and specialty therapies, and guided companies through significant acquisitions, integrations, and capital formation. His experience as a chief executive, together with his public company board service, will be a valuable addition to the Company’s board as the Company moves into its next phase.”

Mr. Daly said, “I am pleased to be joining the Aquestive Board of Directors at an important time for the Company. Anaphylm has the potential to change how patients treat severe allergic reactions, including anaphylaxis. I have spent my career preparing organizations for moments like this one, and I look forward to working with the Board and the management team as Aquestive prepares for its potential launch.”

About Richard Daly

Rich Daly is a life sciences executive with more than 30 years of leadership experience spanning large pharmaceutical companies, emerging biotechnology companies, and public company boards. He currently serves as President of Global Rare Disease at Angelini Pharma S.p.A. following Angelini’s acquisition of Catalyst Pharmaceuticals, Inc., where Mr. Daly served as President and Chief Executive Officer. At Catalyst, Mr. Daly served as President and Chief Executive Officer and oversaw the company’s commercial and business-development activities, including the U.S. launch of Agamree®.

Earlier in his career, Mr. Daly held senior commercial and operating roles at Takeda Pharmaceutical Company Limited, including Executive Vice President, Americas, where he led the company’s Americas business and directed the integration of TAP Pharmaceuticals, Inc. into Takeda, and at AstraZeneca, where as President of the U.S. Diabetes business he oversaw the launches of Farxiga® and Myalept®. He began his biopharmaceutical career at Abbott Laboratories. In biotechnology, Mr. Daly served as Chairman and Chief Executive Officer of Neuralstem, Inc., Chief Operating Officer of BeyondSpring Pharmaceuticals, Inc., Chief Operating Officer and a board member of Seed Therapeutics, Inc., and President of CARsgen Therapeutics Holdings Limited. He previously served on the boards of directors of Catalyst Pharmaceuticals, Inc., Opiant Pharmaceuticals, Inc., Neuralstem, Inc., and Synergy Pharmaceuticals, Inc., where he chaired the Nominating and Governance Committee and served on the Compensation Committee.

About Aquestive

Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies. The worldwide leader in delivering trusted, quality medications on oral film, Aquestive operates as both a developer of its own proprietary products and a Contract Development and Manufacturing Organization (CDMO) for licensees, with its headquarters in New Jersey and U.S.-based manufacturing facilities in Indiana. The Company is the exclusive manufacturer of four commercialized products marketed by its licensees across six continents using proprietary, best-in-class technologies like PharmFilm®. Aquestive’s AdrenaVerse™ platform contains a library of more than 20 epinephrine prodrugs enabling the pursuit of various potential allergy and dermatological indications. The Company is advancing Anaphylm™ (dibutepinephrine) sublingual film for the treatment of Type I allergic reactions, including anaphylaxis, and AQST-108 (epinephrine) topical gel for various potential dermatological conditions. For more information, visit Aquestive.com and follow us on LinkedIn.

Forward-Looking Statement

Certain statements in this press release include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the advancement and related timing of Anaphylm™ (dibutepinephrine) sublingual film for the proposed indication of severe allergic reactions, including anaphylaxis through the U.S. Food and Drug Administration regulatory review and approval process and commercial launch; the potential benefits Anaphylm could bring to patients, and other statements that are not historical facts.

These forward-looking statements are based on our current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with the Company’s development work, including delays to the timing, costs and success of its product development activities, clinical trials and regulatory applications, including relating to Anaphylm (dibutephinephrine) sublingual film, and other uncertainties affecting the Company described in the “Risk Factors” section and elsewhere in the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission. Given those uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by this cautionary statement. The Company undertakes no obligation to update any forward-looking statement after the date of this press release, whether as a result of new information, future events or otherwise, except as required by applicable law.

PharmFilm® and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc. All other registered trademarks referenced herein are the property of their respective owners.

Investor inquiries:
astr partners
Brian Korb
brian.korb@astrpartners.com

MONTRÉAL, Sept. 29, 2026 (GLOBE NEWSWIRE) — Falco Resources Ltd. (TSX-V: FPC) (“Falco” or the “Corporation”) is pleased to announce the results of a third-party Socioeconomic Impact Study (the “Report”) conducted by KPMG LLP (“KPMG”) for the Corporation’s Horne 5 Project located in Rouyn-Noranda, Québec, Canada (the “Horne 5 Project” or the “Project”). The Report outlines the significant economic and labour opportunities of the Horne 5 Project, based on the Project’s updated feasibility study report filed on July 27, 2026, under the Corporation’s profile on SEDAR+ at www.sedarplus.ca (the “2026 Feasibility Study”).

The Report confirms that over the Project’s anticipated lifespan, its direct and indirect contribution to Gross Domestic Product (“GDP”) within the Québec economy at the provincial level is currently estimated at $8.8 billion. The complete Report is available on the Corporation’s website at www.falcores.com (in French only).

Luc Lessard, Falco’s President and CEO, stated: “KPMG’s analysis demonstrates the scale of Horne 5’s potential economic contribution to Québec, and particularly Abitibi-Témiscamingue. With an estimated $8.8 billion contribution to the Québec GDP, more than 22,800 direct and indirect jobs in person-years and approximately $5.1 billion in municipal, provincial and federal tax revenues over the Project’s life, Horne 5 has the potential to generate substantial and lasting economic benefits. Importantly, KPMG estimates that 82% of the value added generated in Québec would accrue to Abitibi-Témiscamingue, reinforcing the Project’s significance to the region.”

Key Highlights from KPMG’s Report (figures and timelines are estimates)

KPMG’s analysis considers approximately $12.1 billion of Project expenditures over 15 years, including pre-production investments, recurring operating costs, and site maintenance and reclamation expenses.

Economic Impact of the Horne 5 Project

Pre-Production & Construction Phase (4 Years)

• Provincial Impact (Québec): $914.4 million in GDP ($228.6 million per year), 4,318 jobs in person-years and $59.4 million in provincial tax revenue.
• Regional Impact (Abitibi-Témiscamingue): $644.6 million in GDP ($161.1 million per year), 2,075 jobs in person-years, and $3.5 million in local tax revenue.
• $32.7 million in federal tax revenue.

Operational and Closure Phases (15 Years)

• Provincial Impact: $7.9 billion in GDP ($524.5 million per year), 18,485 jobs in person-years, and $3.5 billion in provincial tax revenue ($233.6 million per year).
• Regional Impact: $6.5 billion in GDP ($435.8 million per year),11,808 jobs in person-years, and $37.5 million in local tax revenue.
• $1.4 billion in federal tax revenue ($95.6 million per year).

Overall, 82% of the direct and indirect added value generated by the Project is expected to accrue to the Abitibi-Témiscamingue region, which is expected to retain 61% of the jobs supported by the Project.

Additional Highlights from KPMG’s Report

• Workforce Development: The Horne 5 Project will support workforce training and skills development, with a focus on trades and technical roles.
• Local Community: Significant employment and business opportunities, in addition to infrastructure improvements.
• Environmental Sustainability: Falco is committed to minimizing the Project’s environmental footprint through the use of modern technologies, responsible water and tailings management, and the reuse of existing mining infrastructure wherever practicable.
• Supply Chain and Export Potential: The Project will strengthen provincial supply chain for critical minerals.
• Government Alignment: The Project supports Québec and Canada’s strategic priorities for critical minerals and responsible resource development, while contributing to domestic mineral supply and long-term economic growth.

About Falco

Falco is one of the largest mineral claim holders in the province of Québec, with an extensive portfolio of properties in the Abitibi-Témiscamingue greenstone belt. Falco holds rights to approximately 60,000 hectares of land in the Noranda Camp, which includes 13 former gold and base metal mine sites. Falco’s main asset is the Horne 5 Project located beneath the former Horne mine, which was operated by Noranda from 1927 to 1976 and produced 11.6 million ounces of gold and 2.5 billion pounds of copper. Osisko Gold Group Inc. is Falco’s largest shareholder, with a 16.0% interest in the Corporation.

For further information, please contact:

Luc Lessard
President and Chief Executive Officer and Director
514-261-3336
info@falcores.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking information within the meaning of applicable securities laws (“forward-looking statements”). Forward-looking statements are typically identified by words such as: “believe”, “envisions”, “estimates”, “assumes”, “evaluates”, “inferred”, “probability”, “planned”, “projected”, “ensure” “anticipates”, “contemplated”, “expected”, “anticipate” and similar expressions, or that events or conditions “would”, “will”, “can”, or may” occur. All statements that are not statements of historical fact are forward-looking statements.

Forward-looking statements in this press release include, without limitation, statements regarding the projections and assumptions of the Report, including, without limitation: expected direct and indirect Québec and regional GDP contribution from the Project; expected federal, provincial and local tax revenue; and economic assumptions and sensitivities and other operational and economic projections with respect to the Horne 5 Project as well as benefits of the Project for the community.

Although the Corporation believes the forward-looking statements in this press release are reasonable, it can give no assurance that the expectations and assumptions in such statements will prove to be correct. Consequently, the Corporation cautions investors that any forward-looking statements by the Corporation are not guarantees of future results or performance and that actual results may differ materially from those in forward-looking statements.

The forward-looking statements contained herein is subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements, including, without limitation: the effects of general economic conditions; changing foreign exchange rates; risks associated with exploration and project development; the calculation of mineral resources and reserves; risks related to fluctuations in metal prices; uncertainties related to raising sufficient financing to fund the planned work in a timely manner and on acceptable terms; changes in planned work arising from weather, logistical, technical or other factors; the possibility that results of work will not fulfill expectations and realize the perceived potential of the Corporation’s properties; risk of accidents, equipment breakdowns and labour disputes; access to project funding or other unanticipated difficulties or interruptions; the possibility of cost overruns or unanticipated expenses in the work program; title matters; government regulation; obtaining and receiving necessary licenses; the risk of environmental contamination or damage resulting from Falco’s operations, the risk that the conditions precedent to the ability to conduct dewatering or mining activities under the operating license and indemnity agreement (“OLIA”) dated January 23, 2024 between Falco and Glencore Canada Corporation (“Glencore”) may not be satisfied; the risk that Falco may not obtain the required financial assurances to be provided to Glencore, or the financing required to develop or operate the Horne 5 Project; the risk that the required permits and authorizations required from governmental authorities to develop and operate the Horne 5 Project may not be obtained on the terms contemplated or at all; the risk that the OLIA may be terminated in accordance with its terms in the event of default or certain other triggers relating to delays in the commencement of dewatering or mining activities; the risk that, once commenced, certain operations of the Horne 5 Project may have to be suspended, altered or modified pursuant to the conditions of the OLIA; the risk that Glencore may require modifications to Falco’s operations at the Horne 5 Project pursuant to the OLIA which would render the operations less profitable or not profitable (compared to expectations included in the 2026 Feasibility Study); the risk that Falco may incur significant losses and other obligations under its indemnities in favour of Glencore contemplated in the OLIA; and other risks and uncertainties including those described in the Corporation’s Management’s Discussion & Analysis for the three-month and nine-month period ended March 31, 2026, dated May 20, 2026 available at www.sedarplus.ca.

The forward-looking statements contained in this news release are based on the beliefs, estimates and opinions of Falco’s management on the date the statements are made. Although Falco has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Corporation is under no obligation to update or alter any forward-looking statements except as required under applicable securities laws.